<DOC>
	<DOC>NCT00004840</DOC>
	<brief_summary>OBJECTIVES: I. Assess the efficacy and safety of antenatal administration of thyrotropin-releasing hormone to women in premature labor to improve pulmonary outcomes in preterm infants.</brief_summary>
	<brief_title>Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm Infants</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized, double blind, multicenter study. Patients are randomized to receive antenatal thyrotropin-releasing hormone or placebo. Patients receive thyrotropin-releasing hormone or placebo intravenously over 20 minutes every 8 hours for 4 doses. Infants are assessed for survival and chronic lung disease until day 28 after birth, and again at 36 postmenstrual weeks.</detailed_description>
	<mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Thyrotropin-Releasing Hormone</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<criteria>Pregnant women in active labor with 2429 weeks gestation Not eligible if any of the following is present: Bleeding Infection Hypertension (greater than 140/90 mmHg) Fetus with hydrops or lifethreatening anomalies One dead fetus in multiple pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>October 1998</verification_date>
	<keyword>cardiovascular and respiratory diseases</keyword>
	<keyword>neonatal disorders</keyword>
	<keyword>rare disease</keyword>
	<keyword>respiratory distress syndrome</keyword>
</DOC>